FDA again reviews antidepressants

Plan B: Politics and values at the FDA, again.

tive that the U.S. Food and Drug Administration approved for prescription use in 1999. In 2003, a company called Barr Pharmaceuticals submitted to the FDA an application to switch Plan B from prescription to overthe-counter (OTC) status. At a joint meeting late that year, the FDA’s Nonprescription Drugs Advisory Committee and Advisory Committee for Reproductive Health Drugs recommended that the...

Pediatric prescribing practices and the FDA Black-box warning on antidepressants.

BACKGROUND Since the FDA Black box warning in 2004, there has been a 58% drop in antidepressant use among children and adolescents with depression. Paralleling this decrease is an associated increase in completed suicides in youth. To date, no study has examined, on a clinician level, the changes in practice that have occurred subsequent to the FDA warning. OBJECTIVE To examine changes in ped...

More data needed to interpret link between suicide and FDA warning on antidepressants.

Blue Again: Perturbational Effects of Antidepressants Suggest Monoaminergic Homeostasis in Major Depression

Some evolutionary researchers have argued that current diagnostic criteria for major depressive disorder (MDD) may not accurately distinguish true instances of disorder from a normal, adaptive stress response. According to disorder advocates, neurochemicals like the monoamine neurotransmitters (serotonin, norepinephrine, and dopamine) are dysregulated in major depression. Monoamines are normall...

again, you should read again

0